Библиография на научни публикации за мелатонин

Attele AS, Xie JT, Yuan CS. Treatment of insomnia: an alternative approach. Altern Med Rev . 2000;5(3):249-259.

Avery D, Lenz M, Landis C. Guidelines for prescribing melatonin. Ann Med . 1998;30(1):122-130.

Baumgaertel A. Alternative and controversial treatments for attention-deficit/hyperactivity disorder. Pediatr Clin N Am . 1999;46(5):977-992.

Bazil CW, Short D, Crispin D, Zheng W. Patients with intractable epilepsy have low melatonin, which increases following seizures. Neurology . 2000;55(11):1746-1748.

Bekaroglu M, Aslan Y, Gedik Y. Relationships between serum free fatty acids and zinc, and attention deficit hyperactivity disorder: a research note. J Child Psychol Psychiatry . 1996;37(2):225-227.

Ben-Nathan D, Maestroni GJ, Lustig S, Conti A. Protective effects of melatonin in mice infected with encephalitis viruses. Arch Virol . 1995;140(2):223-230.

Bonilla E, Valero-Fuenmayor N, Pons H, Chacin-Bonilla L. Melatonin protects mice infected with Venezuelan equine encephalomyelitis virus. Cell Mol Life Sci . 1997;53(5):430-434.

Brzezinski A. "Melatonin replacement therapy" for postmenopausal women: is it justified? Menopause . 1998;5:60-64.

Bylesjo I, Forsgren L, Wetterberg L. Melatonin and epileptic seizures in patients with acute intermittent porphyria. Epileptic Disord . 2000;2(4):203-208.

Cagnoni ML, Lombardi A, Cerinic MC, Dedola GL, Pignone A. Melatonin for treatment of chronic refractory sarcoidosis [letter]. Lancet . 1995;346(4):1299-1230.

Carman JS, Post RM, Buswell R, Goodwin FK. Negative effects of melatonin on depression. Am J Psychiatry. 1976;133:1181-1186.

Cauffield JS, Forbes HJ. Dietary supplements used in the treatment of depression, anxiety, and sleep disorders. Lippincotts Prim Care Pract . 1999; 3(3):290-304.

Chase JE, Gidal BE. Melatonin: Therapeutic use in sleep disorders. Ann Pharmacother . 1997;31:1218-1225.

Coker KH. Meditation and prostate cancer: integrating a mind/body intervention with traditional therapies. Sem Urol Onc . 1999;17(2):111-118.

Cornelissen G, Halberg F, Burioka N, Perfetto F, Tarquini R, Bakken EE. Do plasma melatonin concentrations decline with age? Am J Med . 2000;109(4):343-345.

Cos S, Sanchez-Barcelo EJ. Melatonin and mamary pathological growth. Frontiers Neuroendo . 2000;21:133-170.

Cos S, Sanchez-Barcelo EJ. Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histo Histopath . 2000;15:637-647.

Dagan Y, Zisapel N, Nof D, et al. Rapid reversal of tolerance to benzodiazepine hypnotics by treatment with oral melatonin: a case report. Eur Neuropsychopharmacol . 1997;7(2):157-160.

Dreher F, Denig N, Gabard B, Schwindt DA, Maibach HI. Effect of topical antioxidants on UV-induced erythema formation when administered after exposure. Dermatology . 1999;198(1):52-55.

Dreher F, Gabard B, Schwindt DA, Maibach HI. Topical melatonin in combination with vitamins E and C protects skin from ultraviolet-induced erythema: a human study in vivo. Br J Dermatol . 1998;139(2):332-339.

Eck-Enriquez K, Kiefer TL, Spriggs LL, Hill SM. Pathways through which a regimen of melatonin and retinoic acid induces apoptosis in MCF-7 human breast cancer cells. Breast Cancer Res Treat . 2000;61(3):229-239.

Fauteck J, Schmidt H, Lerchl A, Kurlemann G, Wittkowski W. Melatonin in epilepsy: first results of replacement therapy and first clinical results. Biol Signals Recept . 1999;8(1-2):105-110.

Ferini-Strambi L, Zucconi M, Biella G, et al. Effect of melatonin on sleep microstructure: preliminary results in healthy subjects. Sleep . 1993;16(8):744-747.

Forsling ML, Wheeler MJ, Williams AJ. The effect of melatonin administration on pituitary hormone secretion in man. Clin Endocrinol (Oxf). 1999;51(5):637-642.

Fraschini F, Demartini G, Esposti D, Scaglione F. Melatonin involvement in immunity and cancer. Biol Signals Recept . 1998;7(1):61-72.

Garfinkel D, Laundon M, Nof D, Zisapel N. Improvement in sleep quality in elderly people by controlled-release melatonin (see comments). Lancet . 1995;346(8974):541-544.

Garfinkel D, Zisapel N, Wainstein J, Laudon M. Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Arch Intern Med . 1999;159(8):2456-2460.

Gibb JW, Bush L, Hanson GR. Exacerbation of methamphetamine-induced neurochemical deficits by melatonin. J Pharmacol and Exp Ther . 1997;283:630-635.

Gordon N. The therapeutics of melatonin: a paediatric perspective. Brain Dev . 2000;22(4):213-217.

Haimov I, Laudon I, Zisapel N, Souroujon M, Nof D, Shiltner A, et al. Sleep disorders and melatonin rhythms in elderly people. BMJ . 1994(9120);309:167.

Herxheimer A, Petrie KJ. Melatonin for preventing and treating jet lag. Cocharane Database Syst Rev. 2001;(1):CD001520.

Jacobson JS, Workman SB, Kronenberg F. Research on complementary/alternative medicine for patients with breast cancer: a review of the biomedical literature. J Clin Onc . 2000;18(3):668-683.

Jan JE, Espezel H, Appleton RE. The treatment of sleep disorders with melatonin. Dev Med Child Neurol . 1994;36(2):97-107.

Jan JE, Espezel H, Freeman RD, Fast DK. Melatonin treatment of chronic sleep disorders. J Child Neurol . 1998; 13(2):98.

Kaneko S, Okumura K, Numaguchi Y, Matsui H, Murase K, Mokuno S, et al. Melatonin scavenges hydroxyl radical and protects isolated rat hearts from ischemic reperfusion injury. Life Sciences . 2000;67(2):101-112.

Kennedy SH. Melatonin disturbances in anorexia nervosa and bulimia nervosa. Int J   Eating Disord . 1994;16:257-265.

Kirkwood CK. Management of insomnia. J Am Pharm Assoc. 1999;39(1):688-696.

Lagneux C, Joyeux M, Demenge P, Ribuot C, Godin-Ribuot D. Protective effects of melatonin against ischemia-reperfusion injury in the isolated rat heart. Life Sciences . 2000;66(6):503-509.

Lewy AJ, Bauer VK, Cutler NL, Sack RL. Melatonin treatment of winter depression: a pilot study. Psych Res . 1998;77(1):57-61.

Lissoni P, Barni S, Meregalli S, Fossati V, Cazzaniga M, Esposti D, Tancini G. Modulation of cancer endocrine therapy to melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer . 1995;71(4):854-856.

Lissoni P, Barni S, Tancini G, Ardizzoia A, Ricci G, Aldeghi R, et al. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer . 1994;69(1):196-199.

Lissoni P, Cazzaniga M, Tancini G, Scardino E, Musci R, Barni S, Maffezzini M, Meroni T, Rocco F, Conti A, Maestroni G. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone. Eur Urol. 1997;31(2):178-181.

Lissoni P, Paolorossi F, Tancini G, et al. A phase II study of tamoxifen plus melatonin in metastic solid tumour patients. Br J Cancer . 1996;74(9):1466-1468.

Lissoni P, Paolorossi F, Tancini G, Barni S, Ardizzoia A, Brivio F, Zubelewicz B, Chatikhine V. Is there a rold for melatonin in the treatment of neoplastic cachexia? Eur J Cancer . 1996;32A(8):1340-1343.

Lissoni P, Tancini G, Barni S, Paolorossi F, Ardizzoia A, Conti A, Maestroni G. Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care Cancer . 1997;5(2):126-129.

Lissoni P, Tancini G, Paolorossi F, Mandala M, Ardizzoia A, Malugani F, et al. Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. J Pineal Res . 1999;26(3):169-173.

Lissoni, P, Vigore L, Rescaldani R, et al. Neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase-II study. J Biol Regul Homeost Agents . 1995;9:155–158.

Low Dog T, Riley D, Carter T. Traditional and alternative therapies for breast cancer. Alt Ther . 2001;7(3):36-47.

Lusardi P, Piazza E, Fogari R. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. Br J Clin Pharmacol . 2000;49(5):423-7.

MacIntosh A. Melatonin: clinical monograph. Q Rev Nat Med . 1996; 47–60.

Manev H, Uz T. Oral melatonin in neurologicaly disabled children [letter]. Lancet . 1998;351:1963.

Massion AO, Teas J, Hebert JR, Wertheimer MD, Kabat-Zinn J. Meditation, melatonin and breast/prostate cancer: hypothesis and preliminary data. Med Hypo . 1995;44:39-46.

Moretti RM, Marelli MM, Maggi R, Dondi D, Motta M, Limonta P. Antiproliferative action of melatonin on human prostate cancer LNCaP cells. Oncol Rep . 2000;7(2):347-351.

Munoz-Hoyos A, Sanchez-Forte M, Molina-Carballo A, Escames G, Martin-Medina E, Reiter RJ, et al. Melatonin's role as an anticonvulsant and neuronal protector: experimental and clinical evidence. J Child Neurol . 1998;13(10):501-509.

Murphy P, Myers B, Badia P. NSAIDs suppress human melatonin levels. Am J Nat Med . 1997; iv: 25.

Nagtagaal JE, Laurant MW, Kerkhof GA, Smits MG, van der Meer YG, Coenen AM. Effects of melatonin on the quality of life in patients with delayed sleep phase syndrome. J Psychosom Res . 2000;48(1):45-50.

Neri B, de Leonardis V, Gemelli MT, di Loro F, Mottola A, Ponchietti R, Raugei A, Cini G. Melatonin as biological response modifier in cancer patients. Anticancer Res . 1998;18(2B):1329-1332.

Oosthuizen JM, Bornman MS, Barnard HC, Schulenburg GW, Boomker D, Reif S. Melatonin and steroid-dependent carcinomas. Andrologia . 1989;21(5):429-431.

Partonen T. Short note: melatonin-dependent infertility. Med Hypotheses . 1999;52(5):487-488.

Peled N, Shorer Z, Peled E. Pillar G. Melatonin effect on seizures in children with severe neurologic deficit disorders. Epilepsia . 2001;42(9):1208-1210.

Petrie K, Conaglen JV, Thompson L, Chamberlain K. Effect of melatonin on jet lag after long haul flights. BMJ . 1989;298:705–707.

Pillar G, Shahar E, Peled N, Ravid S, Lavie P, Etzioni A. Melatonin improves sleep-wake patterns in psychomotor retarded children. Pediatr Neurol . 2000;23(3):225-228.

Ram PT, Yuan L, Dai J, Kiefer T, Klotz DM, Spriggs LL, et al. Differential responsiveness of MCF-7 human breast cancer cell line stocks to the pineal hormone, melatonin. J Pineal Res . 2000;28(4):210-218.

Rommel T, Demisch L. Influence of chronic beta-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension. J Neural Transm Gen Sect . 1994;95:39-48.

Roth JA, Kim B-G, Lin W-L, Cho M-I. Melatonin promotes osteoblast differentiation and bone formation . J Biol Chem . 1999;274:22041-22047.

Sack RL, Brandes RW, Kendall AR, Lewy AJ. Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med. 2000;343(15):1070-1077.

Sack RL, Hughes RJ, Edgar DM, Lewy AJ. Sleep-promoting effects of melatonin: at what dose, in whom, under what conditions, and by what mechanisms? Sleep . 1997;20(10):908-915.

Sakotnik A, Liebmann PM, Stoschitzky K, Lercher P, Schauenstein K, Klein W, et al. Decreased melatonin synthesis in patients with coronary artery disease. Eur Heart J . 199;20(18):1314-1317.

Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psych . 2001;58(11):1049-1052.

Shamir E, Laudon M, Barak Y, Anis Y, Rotenberg V, Elizur A, Zisapel N. Melatonin improves sleep quality of patients with chronic schizophrenia. J Clin Psychiatry . 2000;61(5):373-377.

Shannon M. Alternative medicines toxicology: a review of selected agents. Clin Tox . 1999;37(6):709-713.

Sheldon SH. Oral melatonin in neurologicaly disabled children [letter]. Lancet . 1998;351(9120):1964.

Sheldon SH. Pro-convulsant effects of oral melatonin in neurologically disabled children[letter]. Lancet . 1998;351(9111):1254.

Skene DJ, Lockley SW, Arendt J. Use of melatonin in the treatment of phase shift and sleep disorders. Adv Exp Med Biol . 1999;467:79-84.

Smits MG, Nagtegaal EE, van der Heijden J, Coenen AM, Kerkhof GA. Melatonin for chronic sleep onset insomnia in children: a randomized placebo-controlled trial. J Child Neurol . 2001;16(2):86-92.

Spitzer RL, Terman M, Williams JB, Terman JS, Malt UF, Singer F, et al. Jet lag: clinical features, validation of a new syndrome-specific scale, and lack of response to melatonin in a randomized, double-blind trial. Am J Psych . 1999;156(9):1392-1396.

Stewart LS. Endogenous melatonin and epileptogenesis: facts and hypothesis. Int J Neurosci . 2001;107(1-2):77-85.

Stoschitzky K, Sakotnik A, Lercher P, Zweiker R, Maier R, Liebmann P, Lindner W. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol . 1999;55(2):111-115.

Tzischinsky O, Lavie P. Melatonin possesses time-dependent hypnotic effects. Sleep . 1994;17:638–645.

van Wijingaarden E, Savitz DA, Kleckner RC, Cai J, Loomis D. Exposure to electromagnetic fields and suicide among electric utility workers: a nested case-control study. West J Med . 2000;173;94-100.

Wagner DR. Circadian rhythm sleep disorders. Curr Treat Opt Neurol. 1999;1(4):299-308.

Wagner J, Wagner ML, Hening WA. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother . 1998; 32:680-691.

Walsh HA, Daya S. Influence of the antidepressants desipramine and fluoxetine on tryptophan-2,3-dioxygenase in the presence of exogenous melatonin. Life Sci . 1998;62(26):2417-2423.

Weekley LB. Melatonin-induced relaxation of rat aorta: Interaction with adrenergic agonists. J Pineal Res . 1991;11:28-34.

West Sk, Oosthuizen JM. Melatonin levels are decreased in rheumatoid arthritis. J Basic   Clin Physiol Pharmacol . 1992;3(1):33-40.

Wurtman RJ, Zhdanova II. Oral melatonin in neurologicaly disabled children [letter]. Lancet . 1998;351(9120):1963-1964.

Zawilska JB, Nowak JZ. Melatonin: from biochemistry to therapeutic applications. Pol J Pharm . 1999;51:3-23.

Zeitzer JM, Daniels JE, Duffy JF, Klerman EB, Shanahan TL, Dijk DJ et al. Do plasma melatonin concentrations decline with age? Am J Med . 1999;107(5):432-436.

Zhdanova IV, Wurtman RJ, Morabito C, Piotrovska VR, Lynch HJ. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep . 1996;19:423–431.

Zhdanova IV, Wurtman RJ, Lynch HJ, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther . 1995; 57:552–558.